The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 18, 2018

Filed:

Feb. 14, 2017
Applicant:

Bordoloi Biotech, Llc, Bridgewater, NJ (US);

Inventors:

Binoy K Bordoloi, Bridgewater, NJ (US);

Nayan J Sarma, Kamamazoo, MI (US);

Rodney L. Eisenberg, Richmond, KY (US);

Assignee:

Bordoloi Biotech, LLC, Bridgewater, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/195 (2006.01); A61K 9/16 (2006.01); A61K 9/00 (2006.01); A61L 31/16 (2006.01); A61L 24/00 (2006.01); A61L 24/04 (2006.01); A61L 26/00 (2006.01); A61K 9/14 (2006.01); A61K 9/50 (2006.01);
U.S. Cl.
CPC ...
A61K 31/195 (2013.01); A61K 9/0053 (2013.01); A61K 9/14 (2013.01); A61K 9/1647 (2013.01); A61K 9/50 (2013.01); A61L 24/001 (2013.01); A61L 24/0015 (2013.01); A61L 24/0042 (2013.01); A61L 24/043 (2013.01); A61L 26/009 (2013.01); A61L 26/0052 (2013.01); A61L 26/0061 (2013.01); A61L 26/0066 (2013.01); A61L 31/16 (2013.01); A61L 2300/418 (2013.01); A61L 2300/434 (2013.01); A61L 2300/604 (2013.01); A61L 2300/622 (2013.01); A61L 2400/04 (2013.01);
Abstract

The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid ('TA'). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce a protease inhibitor formulation. Next, the formulation along with fibrinogen and thrombin is applied to a wound site where an outer surface of the polymer microsphere degrades in a proteolytic environment to expose and release the incorporated protease inhibitor to the surrounding hydrogel or sealant or clot matrix at the wound site.


Find Patent Forward Citations

Loading…